Hairy Bracket

Metadata

Regulatory Status

No Pharmacopoeial Recognition

• Trametes hirsuta is not listed in any national pharmacopoeia (Chinese, Japanese, Korean, European, or US) as a medicinal product.
• It has no documented history of systematic use in any traditional medicine system, distinguishing it from its close relative T. versicolor, which has extensive TCM and Kampo traditions.
• Research interest in T. hirsuta has been driven primarily by bioactive screening programs, biodiversity surveys, and its industrial significance as a laccase producer rather than by traditional medicinal use.

United States

• FDA status: Not approved as a drug. Not marketed as a dietary supplement.
• No GRAS determination.

European Union

• Novel food status: Not authorized. No specific evaluation.
• No EMA/HMPC monograph.
• Biotechnological recognition: T. hirsuta laccase enzymes have been investigated for industrial applications in the EU, including textile dye decolorization, bioremediation, and food processing, but this does not confer medicinal or food approval status.

China and Japan

• Not recognized in either traditional Chinese medicine or Japanese Kampo medicine.
• Biotechnological interest: Chinese research institutions have investigated T. hirsuta for lignocellulose degradation and environmental remediation applications.

Conditions & Indications

Primary: Antimicrobial Activity (Preclinical Evidence)

• Antibacterial effects: Ethanol and aqueous extracts of T. hirsuta demonstrate antibacterial activity against both Gram-positive and Gram-negative bacteria in vitro. Activity has been reported against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. The phenolic compound fraction (gallic acid, protocatechuic acid) appears to drive much of the antibacterial activity, though polysaccharide fractions also contribute.
• Antifungal effects: Extracts demonstrate activity against pathogenic fungi including Candida albicans and Aspergillus species in vitro. The antifungal mechanism appears to involve disruption of cell membrane integrity.
• Potential for multi-drug-resistant pathogens: Some studies have noted activity against methicillin-resistant Staphylococcus aureus (MRSA), though the evidence is limited and requires replication.

Secondary: Antioxidant and Anti-Inflammatory Effects (Preclinical Evidence)

• Antioxidant activity: Both fruiting body and mycelial extracts demonstrate significant free radical scavenging activity (DPPH, ABTS, hydroxyl radical) and metal chelation capacity. The antioxidant potency is attributed to the phenolic compound profile, with gallic acid and protocatechuic acid as major contributors. Some studies report antioxidant capacity comparable to or exceeding that of synthetic antioxidants (BHT, BHA) at equivalent concentrations.
• Anti-inflammatory activity: Extracts suppress production of pro-inflammatory mediators (NO, TNF-alpha, IL-6) in LPS-stimulated macrophage models. The mechanism involves NF-kB pathway modulation and COX-2 expression suppression.
• Cytoprotective effects: Extracts demonstrate protective effects against H2O2-induced oxidative damage in cell culture models, suggesting potential for cellular protection against oxidative stress.

Emerging/Preclinical

• Immunomodulatory polysaccharides: Beta-glucan polysaccharides from T. hirsuta stimulate macrophage activation and cytokine production in vitro. Given the close phylogenetic relationship to T. versicolor (the source of the clinically validated PSK/PSP polysaccharides), there is interest in whether T. hirsuta polysaccharides share similar immunotherapeutic potential. Preliminary structural characterization suggests comparable backbone structures, but the degree of branching and molecular weight distribution may differ.
• Anti-tumor activity: Crude extracts and polysaccharide fractions demonstrate cytotoxicity against select cancer cell lines in vitro (MCF-7, HeLa, HepG2). Mechanisms appear to involve both direct anti-proliferative effects and immunomodulatory activity. No in vivo anti-tumor studies have been published.
• Bioremediation and environmental health: T. hirsuta is a prolific producer of laccase enzymes, which oxidize a broad range of phenolic and non-phenolic substrates. This has significant implications for environmental health through degradation of environmental pollutants (dyes, pesticides, pharmaceutical residues, polycyclic aromatic hydrocarbons) that may contribute to chronic disease. While not a direct medicinal application, the bioremediation capacity is relevant to the broader One Health framework connecting environmental quality and human health.
• Prebiotic potential: Like other polysaccharide-rich fungi, T. hirsuta extracts may modulate gut microbiota composition, though this has not been specifically investigated.

Mechanism of Action

Primary Mechanisms

1. Phenolic compound-mediated antimicrobial activity: The antimicrobial activity of T. hirsuta is driven primarily by its phenolic compound profile, particularly gallic acid, protocatechuic acid, and catechin. These compounds disrupt bacterial cell membrane integrity through interaction with membrane phospholipids, leading to increased permeability and cell lysis. Additionally, phenolics inhibit bacterial enzyme systems involved in energy metabolism and nucleic acid synthesis. The broad-spectrum activity against both Gram-positive and Gram-negative bacteria suggests multiple targets rather than a single specific mechanism.

2. Polysaccharide-driven immunomodulation: Beta-1,3/1,6-D-glucan polysaccharides from T. hirsuta activate innate immune cells through Dectin-1 and TLR-2 pattern recognition receptors, triggering NF-kB and MAPK signaling cascades that enhance macrophage phagocytic activity, NK cell cytotoxicity, and dendritic cell maturation. This mechanism is shared with T. versicolor and other medicinal polypore species. The structural similarity of T. hirsuta polysaccharides to PSK/PSP from T. versicolor suggests analogous immunotherapeutic potential, though this has not been clinically validated.

3. Antioxidant radical scavenging and metal chelation: The phenolic and flavonoid content of T. hirsuta provides both direct radical scavenging activity (hydrogen atom transfer from hydroxyl groups to free radicals) and indirect antioxidant protection through chelation of pro-oxidant transition metals (Fe2+, Cu2+), preventing Fenton reaction-mediated oxidative damage. Ergosterol contributes additional membrane-protective antioxidant activity.

Secondary Mechanisms

• Laccase-mediated xenobiotic oxidation: T. hirsuta laccase (a multicopper oxidase) catalyzes the one-electron oxidation of a wide range of phenolic and non-phenolic substrates. While this mechanism is primarily relevant to environmental bioremediation, laccase-mediated oxidation of dietary phenolics in the gut could theoretically influence the bioavailability and biological activity of polyphenol metabolites, though this specific application has not been investigated.
• COX-2 and NF-kB suppression: Anti-inflammatory activity proceeds through inhibition of cyclooxygenase-2 (COX-2) expression and suppression of NF-kB nuclear translocation, reducing production of prostaglandins and pro-inflammatory cytokines. This mechanism is shared with many phenolic compound-rich natural products.

Comparison with Trametes versicolor

Clinical Evidence Summary

No human clinical trials have been published for Trametes hirsuta. All pharmacological evidence derives from in vitro studies, with limited animal model data. The species lacks the traditional medicinal use documentation that supports other bracket fungi.

Preclinical Evidence Summary

Evidence Limitations

• No human clinical trials. All evidence is preclinical, with the majority from in vitro studies.
• No traditional medicinal use. Unlike most medicinal mushroom species, T. hirsuta lacks documentation in any traditional medicine system, removing the ethnobotanical evidence layer that supports species like T. versicolor, reishi, or chaga.
• Limited in vivo data. Very few animal model studies have been published. The translation from in vitro to in vivo effects is unknown.
• Overshadowed by T. versicolor. Research attention on Trametes genus medicinal properties has been heavily concentrated on T. versicolor due to the PSK/PSP clinical success story. T. hirsuta has received comparatively minimal research investment.
• Extract variability. Studies use diverse extraction methods (ethanol, aqueous, acetone, submerged culture) and material sources (wild-collected vs. cultivated), making cross-study comparison difficult.
• Antimicrobial significance uncertain. In vitro MIC values are generally in the high microgram range, which may not translate to clinically achievable concentrations after oral administration.
• Polysaccharide characterization incomplete. While structural comparisons to T. versicolor polysaccharides have been initiated, the full structural characterization and comparative immunomodulatory assessment of T. hirsuta polysaccharides remain incomplete.

Safety Profile

General Assessment

Trametes hirsuta has no documented history of significant human consumption for medicinal purposes. The fruiting body is tough and woody, typical of bracket fungi, and is not consumed as food. No formal safety evaluation has been conducted in humans. The safety profile must be considered entirely unknown, though membership in the Trametes genus alongside the well-tolerated T. versicolor provides some taxonomic reassurance.

Contraindications

• Pregnancy and lactation: No safety data. Avoid.
• Polypore allergy: Individuals with known allergy to bracket fungi should avoid use.

Drug Interactions

• No documented drug interactions. The absence of traditional use or clinical data means drug interactions have not been observed or investigated.
• Theoretical immunosuppressant interaction: If polysaccharide immunostimulatory activity parallels that of T. versicolor, concurrent use with immunosuppressants could theoretically reduce efficacy of immunosuppressive therapy.

Side Effects

• Not characterized. No human safety data exist.

Toxicology

• Preclinical: Limited data. Some in vitro studies report selective cytotoxicity against cancer cell lines with lower toxicity to normal cells, but this is insufficient to assess human safety.
• No LD50 data available.
• Heavy metals and environmental contaminants: As a saprophyte on dead wood, T. hirsuta can absorb environmental contaminants from its substrate. Its efficient laccase-mediated degradation of pollutants paradoxically means that specimens growing in contaminated environments may internalize breakdown products. Quality testing is essential.
• Laccase enzyme caution: Crude preparations containing active laccase enzymes could theoretically oxidize dietary phenolics in the gastrointestinal tract, altering their bioavailability and potentially producing reactive intermediates. The clinical significance of this theoretical concern is unknown.

Clinical Dosage

No Established Dosage

No human clinical trials, traditional use records, or pharmacopoeial entries exist to guide dosing of T. hirsuta preparations.

Provisional Estimates (By Analogy Only)

Based solely on analogy with Trametes versicolor and other medicinal polypore species:

• Dried fruiting body powder: 1-3 g/day (estimated by analogy with T. versicolor dosing)
• Hot-water extract: Equivalent to 1-3 g dried fruiting body per day (primarily captures polysaccharides)
• Ethanol extract: No dosing data; would capture phenolic and terpenoid fractions

Critical Note

All dosing suggestions are purely speculative. No evidence of any kind supports specific dosing recommendations for T. hirsuta. The species is not commercially available as a standardized medicinal product. Any use should be considered experimental and undertaken only under practitioner guidance with properly identified and quality-tested material.

Sources

• Awadh Ali NA, Mothanaa RAA, Lesnau A, Pilgrim H, Lindequist U. Antiviral activity of Inonotus hispidus. Fitoterapia. 2003;74(5):483-485
• Matijasevic D, Pantic M, Raskovic B, Pavlovic V, Duvnjak D, Sknepnek A, Niksin-Grubin J. The antibacterial activity of Coriolus versicolor methanol extract and its effect on ultrastructural changes of Staphylococcus aureus and Salmonella Enteritidis. Front Pharmacol. 2016;7:401
• Knezevic A, Milovanovic I, Stajic M, Loncar N, Brceski I, Vukojevic J, Cilerdzic J. Trametes species from Serbia: their antimicrobial, antioxidant, and anticancer properties. Arch Biol Sci. 2018;70(4):631-641
• Songulashvili G, Elisashvili V, Wasser SP, Nevo E, Hadar Y. Basidiomycetes laccase and manganese peroxidase activity in submerged fermentation of food industry wastes. Enzyme Microb Technol. 2007;41(1-2):57-61
• Janjusevic L, Karaman M, Sibul F, Tommonaro G, Iodice C, Jakovljevic D, Pejin B. The lignicolous fungus Trametes versicolor (L.) Lloyd (1920): a promising natural source of antiradical and AChE inhibitory agents. J Enzyme Inhib Med Chem. 2017;32(1):355-362
• Ravlic M, Novak M, Stampar M, Bilusic Vunduk J, Zuzek K, Gregori A, Kreft S, Umek A. Polysaccharides from Trametes hirsuta: structural characterization and immunomodulatory activity. Int J Biol Macromol. 2021;174:526-536
• Elisashvili V, Kachlishvili E, Tsiklauri N, Metreveli E, Khardziani T, Agathos SN. Lignocellulose-degrading enzyme production by white-rot Basidiomycetes isolated from the forests of Georgia. World J Microbiol Biotechnol. 2009;25(2):331-339
• Zjawiony JK. Biologically active compounds from Aphyllophorales (polypore) fungi. J Nat Prod. 2004;67(2):300-310
• Wasser SP. Medicinal mushroom science: current perspectives, advances, evidences, and challenges. Biomed J. 2014;37(6):345-356
• Lindequist U, Niedermeyer TH, Julich WD. The pharmacological potential of mushrooms. Evid Based Complement Alternat Med. 2005;2(3):285-299
• Knezevic A, Stajic M, Milovanovic I, Vukojevic J. Antioxidant and antimicrobial activity of Trametes gibbosa, Trametes hirsuta, and Trametes versicolor: a comparative study. Arch Biol Sci. 2015;67(3):1027-1034
• Gregori A, Svagelj M, Pohleven J. Cultivation techniques and medicinal properties of Pleurotus spp. Food Technol Biotechnol. 2007;45(3):238-249

Connections

• Trametes versicolor (Turkey Tail): Turkey Tail is the most closely related and most extensively studied medicinal species in the Trametes genus. T. versicolor polysaccharides (PSK/Krestin, PSP) are approved pharmaceuticals in Japan and China for cancer adjunctive therapy, representing the clinical validation standard that T. hirsuta polysaccharides would need to approach. The structural similarity between T. hirsuta and T. versicolor polysaccharides suggests analogous immunomodulatory potential, but this remains unvalidated.
• Fomes fomentarius (Tinder Fungus): Tinder Fungus is another common bracket fungus with antimicrobial and anti-inflammatory properties. Both species lack significant clinical evidence despite promising preclinical profiles, highlighting the broader research gap in polypore pharmacology outside of a few well-studied species.
• Schizophyllum commune (Split Gill): Schizophyllum commune shares the polysaccharide-driven immunomodulatory mechanism and has progressed further toward clinical application, with schizophyllan (SPG) approved as an anti-cancer adjuvant in Japan. This provides another model for how T. hirsuta polysaccharides could potentially be developed.
• Reishi (Ganoderma lucidum): Reishi represents the dual polysaccharide-triterpenoid pharmacological model. T. hirsuta is primarily a polysaccharide and phenolic compound species, lacking the rich triterpenoid chemistry of Ganoderma.
• Bioremediation-medicinal nexus: T. hirsuta’s significance as a laccase-producing bioremediation organism connects environmental health to human health. The same enzymatic capacity that enables pollutant degradation in the environment may contribute to the organism’s bioactive profile when consumed, though this translational concept requires investigation.